Lower-dose alteplase could be a game-changer for acute stroke

The controversial clot busting drug rtPA (alteplase) has been given the green light by Australian scientists who have found lowering the dose is effective.

Results from a trial of more than 3000 patients in 100 hospitals worldwide show a modified dosage of rtPA reduces the risk of intracerebral haemorrhage and improves survival rates.

The researchers from the St George Institute for Global Health say they